News Type:

MHRA issues important alert for Emerade 150/300/500mcg auto-injectors 4th March 2020

4th March 2020 The UK’s regulator of medicines (Medicines & Healthcare products Regulatory Agency [MHRA]) has received updated information from the company that makes Emerade pens about the defect previously reported by the MHRA. The defect means some pens may

Read more
Survey: Making allergy, skin disease and asthma care better for young people 28th February 2020

Developing new guidance for healthcare professionals looking after teenagers and young adults with allergies and/or asthma. It is important that young people learn how to self-manage their allergies and/or asthma. Adolescence can be a challenging time for them and their

Read more
Food Standards Agency Survey: Improving life for people with Food Hypersensitivity 21st February 2020

The Food Standards Agency (FSA) are inviting those affected or interested in food hypersensitivity to participate in an online survey and share their experiences. Around 2% of adults and 8% of children in the UK have a food hypersensitivity. This

Read more
Latest statement on availability of EpiPen® 0.3mg and 0.15mg Adrenaline Auto-Injectors 14th February 2020

The Anaphylaxis Campaign has received the following updated statement from Mylan regarding the availability of EpiPen. This includes information for patients, prescribers, pharmacists, hospitals and schools. Mylan’s manufacturing partner Meridian Medical Technologies, a subsidiary of Pfizer that manufactures EpiPen®, has

Read more
Statement regarding the death of Sam Collings 13th February 2020

The Anaphylaxis Campaign is saddened to learn of the death of Sam Collings, aged 19,  who died at Bolton Hospital on the 4th August 2019. According to media reports, neither Sam or his family had suspected that Sam suffered from

Read more
First Oral Immunotherapy Drug ‘Palforzia’ gets FDA Approval 3rd February 2020

The Anaphylaxis Campaign is delighted to hear about the success of Aimmune Therapeutics, Inc. in the approval of their oral immunotherapy drug, Palforzia, by the US Food and Drug Administration (FDA). This is the first oral immunotherapy drug that has

Read more
Clinicians & Charities Call For Urgent Action to Keep Food Allergic Children Safe in School 29th January 2020

An editorial in the February edition of Clinical and Experimental Allergy (the official journal of the British Society of Allergy and Clinical Immunology) explores the current statutory guidance on the care of children with medical conditions in schools, and highlights

Read more
Positive results in peanut allergy treatment trials 27th January 2020

Biopharmaceutical company DBV Technologies has announced positive results from its Viaskin® Peanut trial into reducing the risk of allergic reaction in children aged 4 to 11. Viaskin is a patch applied directly to the surface of the skin and contains

Read more
Update from Sacla regarding pesto recall 20th January 2020

The Anaphylaxis Campaign has received and has been asked to share the following update from Sacla regarding its recent pesto recall. Update from Sacla: Customer health and safety is always our number one priority. In December, when we became aware that cashew

Read more